Skip to content

Phentolamine Mesylate as a Reversal of Local Anesthesics

Phentolamine Mesylate as a Reversal of Local Anesthesics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03740386
Enrollment
90
Registered
2018-11-14
Start date
2016-01-01
Completion date
2018-11-09
Last updated
2018-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Local

Keywords

phentolamine mesylate, reverse local anesthesia

Brief summary

Oraverse © (Phentolamine mesylate) is a product designed to reverse the effect of local anesthetics used in dentistry. Its main objective is to reduce the postoperative period during which the patient suffers from the lack of sensitivity in the perioral soft tissues, it is an obvious discomfort, a difficulty to speak or eat, and sometimes a risk of self-injury in the lips and / or tongue . The product was approved by the FDA in 2008 although the introduction in Spain has not occurred until December 2015. There are numerous studies that support its use, its effectiveness and safety, although none of the Spanish population, who have not yet had the opportunity to experience it.

Detailed description

PURPOSE OF THE STUDY: To analyze the response of Oraverse in patients receiving complete oral disinfection treatment, after administration of Lidocaine 2% 1/80000, Articaine 4% 1/200000 or Bupivacaine 0,5% 1:200000 in mandible, in comparison with the contralateral control side.

Interventions

DRUGPhentolamine Mesylate 0.235 MG/ML [OraVerse]

compare effect of phentolamine mesylate in three arms

Sponsors

León Formación
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

We use a program to randomize three groups. Double blind study No sham or placebo

Intervention model description

Three randomized groups

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Previously diagnosticated to receive dental treatment according to Leonformacion's criteria

Exclusion criteria

* Hepatic or renal patient * Fertility treatment, pregnancy or lactation * Treatment with oral anticoagulants * Patients with known allergies to anesthetics, excipients or phentolamine mesylate * Patients with previous facial paresthesia * Patients who had taken any painkiller or anti-inflammatory the day before * Patients in which the anesthetic technique fails or has to be reinforced with more than two carpules

Design outcomes

Primary

MeasureTime frameDescription
time lip recovery fron local anesthesia1 dayself reported lip sensitivity by questionaire marking every 15 minutes

Secondary

MeasureTime frameDescription
Post intervention pain1 dayvisual analogue scale to measure pain: Line ranged from 1 to 10 units where 1 means no pain at all and 10 means the worst imaginable pain. Lower levels are good outcomes
post intervention bleeding1 dayclinical assesment of post intervention bleeding when using phentolamine mesylate

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026